STOP THE WAR! Let’s support Ukraine Together

Social Capital Suvretta III (DNAC) to Combine with ProKidney in $1.8Bn Deal

Social Capital Suvretta III (DNAC) to Combine with ProKidney in $1.8Bn Deal

Social Capital Suvretta III (NASDAQ:DNAC) has entered into a definitive combination agreement with biopharmaceutical firm ProKidney at an enterprise value of $1.835 billion. Winston-Salem, North Carolina-based ProKidney has launched Phase III trials of its REACT cellular therapy which promises to slow the progression of chronic kidney disease (CKD) and potentially regenerate tissues and function. The
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.